182 related articles for article (PubMed ID: 34738234)
1. Local and systemic effects of interleukin-6 (IL-6) in inflammation and cancer.
Rose-John S
FEBS Lett; 2022 Mar; 596(5):557-566. PubMed ID: 34738234
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 controls recycling and degradation, but not internalization of its receptors.
Flynn CM; Kespohl B; Daunke T; Garbers Y; Düsterhöft S; Rose-John S; Haybaeck J; Lokau J; Aparicio-Siegmund S; Garbers C
J Biol Chem; 2021; 296():100434. PubMed ID: 33610555
[TBL] [Abstract][Full Text] [Related]
3. Dissecting Interleukin-6 Classic and Trans-signaling in Inflammation and Cancer.
Garbers C; Rose-John S
Methods Mol Biol; 2023; 2691():207-224. PubMed ID: 37355548
[TBL] [Abstract][Full Text] [Related]
4. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.
Rose-John S
Int J Biol Sci; 2012; 8(9):1237-47. PubMed ID: 23136552
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 and its receptors: a highly regulated and dynamic system.
Wolf J; Rose-John S; Garbers C
Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
[TBL] [Abstract][Full Text] [Related]
6. Dissecting Interleukin-6 Classic- and Trans-Signaling in Inflammation and Cancer.
Garbers C; Rose-John S
Methods Mol Biol; 2018; 1725():127-140. PubMed ID: 29322414
[TBL] [Abstract][Full Text] [Related]
7. Effects of blockade of peripheral interleukin-6 trans-signaling on hippocampus-dependent and independent memory in mice.
Braun O; Dewitz C; Möller-Hackbarth K; Scheller J; Schiffelholz T; Baier PC; Rose-John S
J Interferon Cytokine Res; 2013 May; 33(5):254-60. PubMed ID: 23215755
[TBL] [Abstract][Full Text] [Related]
8. The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation.
Rose-John S
Clin Pharmacol Ther; 2017 Oct; 102(4):591-598. PubMed ID: 28675418
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
Chalaris A; Schmidt-Arras D; Yamamoto K; Rose-John S
Dig Dis; 2012; 30(5):492-9. PubMed ID: 23108305
[TBL] [Abstract][Full Text] [Related]
10. Cytokines are a therapeutic target for the prevention of inflammation-induced cancers.
Rose-John S; Schooltink H
Recent Results Cancer Res; 2007; 174():57-66. PubMed ID: 17302185
[TBL] [Abstract][Full Text] [Related]
11. Viral Interleukin-6: Structure, pathophysiology and strategies of neutralization.
Suthaus J; Adam N; Grötzinger J; Scheller J; Rose-John S
Eur J Cell Biol; 2011; 90(6-7):495-504. PubMed ID: 21176991
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
Rose-John S; Scheller J; Elson G; Jones SA
J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
[TBL] [Abstract][Full Text] [Related]
13. Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor.
Adam N; Rabe B; Suthaus J; Grötzinger J; Rose-John S; Scheller J
J Virol; 2009 May; 83(10):5117-26. PubMed ID: 19264784
[TBL] [Abstract][Full Text] [Related]
14. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.
Baran P; Hansen S; Waetzig GH; Akbarzadeh M; Lamertz L; Huber HJ; Ahmadian MR; Moll JM; Scheller J
J Biol Chem; 2018 May; 293(18):6762-6775. PubMed ID: 29559558
[TBL] [Abstract][Full Text] [Related]
15. Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses.
Lamertz L; Rummel F; Polz R; Baran P; Hansen S; Waetzig GH; Moll JM; Floss DM; Scheller J
Sci Signal; 2018 Oct; 11(550):. PubMed ID: 30279168
[TBL] [Abstract][Full Text] [Related]
16. Novel Insights into Interleukin 6 (IL-6) Cis- and Trans-signaling Pathways by Differentially Manipulating the Assembly of the IL-6 Signaling Complex.
Lacroix M; Rousseau F; Guilhot F; Malinge P; Magistrelli G; Herren S; Jones SA; Jones GW; Scheller J; Lissilaa R; Kosco-Vilbois M; Johnson Z; Buatois V; Ferlin W
J Biol Chem; 2015 Nov; 290(45):26943-26953. PubMed ID: 26363066
[TBL] [Abstract][Full Text] [Related]
17. The amino acid exchange R28E in ciliary neurotrophic factor (CNTF) abrogates interleukin-6 receptor-dependent but retains CNTF receptor-dependent signaling via glycoprotein 130 (gp130)/leukemia inhibitory factor receptor (LIFR).
Wagener EM; Aurich M; Aparicio-Siegmund S; Floss DM; Garbers C; Breusing K; Rabe B; Schwanbeck R; Grötzinger J; Rose-John S; Scheller J
J Biol Chem; 2014 Jun; 289(26):18442-50. PubMed ID: 24802752
[TBL] [Abstract][Full Text] [Related]
18. Blocking only the bad side of IL-6 in inflammation and cancer.
Rose-John S
Cytokine; 2021 Dec; 148():155690. PubMed ID: 34474215
[TBL] [Abstract][Full Text] [Related]
19. Cell-autonomous hepatocyte-specific GP130 signaling is sufficient to trigger a robust innate immune response in mice.
Schumacher N; Yan K; Gandraß M; Müller M; Krisp C; Häsler R; Carambia A; Nofer JR; Bernardes JP; Khouja M; Thomsen I; Chalupsky K; Bolik J; Hölscher C; Wunderlich T; Herkel J; Rosenstiel P; Schramm C; Schlüter H; Renné T; Mittrücker HW; Rose-John S; Schmidt-Arras D
J Hepatol; 2021 Feb; 74(2):407-418. PubMed ID: 32987028
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 and its receptor: from bench to bedside.
Scheller J; Rose-John S
Med Microbiol Immunol; 2006 Dec; 195(4):173-83. PubMed ID: 16741736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
